vTv Therapeutics (VTVT) Reports Q2 Loss of $0.47/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts VTVT Hot Sheet
Join SI Premium – FREE
vTv Therapeutics (NASDAQ: VTVT) reported Q2 EPS of ($0.47). Revenue for the quarter came in at $182 thousand, versus $110 thousand reported last year.
Cash, cash equivalents and marketable securities as of June 30, 2016 were $63.8 million, compared to $88.0 million as of December 31, 2015. The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through at least mid-2017.
For earnings history and earnings-related data on vTv Therapeutics (VTVT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Top AI Semiconductor Stocks According to Stifel Analysis
- Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
- Amrize Ltd (AMRZ) PT Lowered to $40 at DA Davidson as FY26 Guidance 'at Risk'
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
